Combined Effects of Mulligan's Mobilization With Movement and Kinetic Control Training on Pain, Range of Motion, Gait and Functional Disability Among Patients With Sacroiliac Joint Dysfunction (MWM KCT SIJD)

May 21, 2026 updated by: Prof. Dr. Shoaib Waqas, Lahore University of Biological and Applied Sciences

Sacroiliac joint dysfunction (SIJD) is a frequent source of low back and pelvic pain and contributes significantly to movement restriction, altered gait patterns, and functional disability in adults. It is associated with impaired lumbopelvic motor control, weakness of key stabilizing muscles, and faulty load transfer across the pelvis. SIJD is prevalent in both physically active individuals and sedentary populations. In addition to its clinical impact, SIJD imposes a considerable socioeconomic burden due to reduced work productivity and long-term disability.

Contemporary management of SIJD emphasises on pain reduction, restoration of movement, functional independence, and participation in daily activities. Manual therapy techniques such as Mulligan's Mobilization with Movement (MWM) are widely used to correct positional faults and restore pain-free movement, while kinetic control training targets deficits in motor control of the lumbopelvic stabilizing muscles. Although both approaches are individually supported in the literature, evidence regarding their combined effectiveness on pain, range of motion, gait parameters, and functional disability remains limited. Therefore, this study aims to compare the effects of combined Mulligan's Mobilization with Movement and kinetic control training versus kinetic control training alone in patients with sacroiliac joint dysfunction using validated outcome measures.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Sacroiliac joint dysfunction (SIJD) refers to altered biomechanics of the sacroiliac joint, characterized by either excessive or restricted movement, or the presence of abnormal motion patterns. It is a recognized source of pain originating from the sacroiliac joint and occurs due to abnormal or increased movement of the ilium relative to the sacrum, leading to irritation of the surrounding joint structures. The prevalence of SIJD among individuals with low back pain has been reported to range from 15% to 30% in Asian populations, including Pakistan. In the Pakistani context, SIJD is frequently observed among healthcare professionals and individuals whose occupations involve prolonged standing or repetitive postural activities. In recent years, the incidence of SIJD appears to be increasing, possibly due to sedentary lifestyles, cumulative mechanical stress, and improved clinical recognition of the sacroiliac joint as a distinct contributor to low back pain.

The clinical diagnosis of SIJD is primarily based on a detailed patient history and focused physical examination, while its management involves a combination of therapeutic approaches. Current management strategies are consistent with the World Health Organization's International Classification of Functioning, Disability and Health (ICF) framework. Two therapeutic approaches of concern in this study are Mulligan's Mobilization with Movement (MWM) and KInetic Control (KC) training.

Mulligan's Mobilization with Movement (MWM) is a manual therapy technique that applies sustained accessory glides during active movement to correct positional faults and alleviate pain. This approach is intended to produce immediate functional improvement by combining pain-free accessory glides with physiological movement. Mobilization of the sacroiliac joint through physiotherapy aims to restore normal joint mechanics, enabling patients to maintain optimal sacroiliac joint function throughout daily activities.

Kinetic Control, as proposed by Comerford and Mottram, focuses on retraining faulty movement patterns to address uncontrolled movement and enhance joint stability. Movement is fundamental to functional performance and participation in daily life, and restoring controlled movement enables individuals to regain the functional choices that are often lost in the presence of pain and movement impairment. This study therefore seeks to compare the effects of Mulligan's MWM combined with kinetic control training targeting the gluteus maximus and multifidus muscles.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
55

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan
        • Not yet recruiting
        • Ali Hospital
      • Lahore, Punjab Province, Pakistan
        • Recruiting
        • Physiotherapy Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Both male and female patients
  • Age between 45- 64 years
  • Unilateral non-radiating pain
  • Confirmed diagnosis through at least 3/5 provocative tests Faber test Distraction test Thigh thrust test Gaenslen test Sacral thrust test
  • Pain rating from 4-6 on Numeric Pain Rating Scale
  • Symptoms of SIJD for more than 2 months

Exclusion Criteria:

  • Patients with history of any surgery at lumbo-sacral or pelvic region
  • Pregnancy, lactation
  • Congenital, postural deformities
  • Acute disc hernia and spinal stenosis that may cause pain in the lower back and hips, piriformis syndrome
  • Rheumatic diseases (fibromyalgia, ankylosing spondylitis, rheumatic arthritis)
  • Acute infections or malignancies
  • Having received manual therapy for the sacroiliac joint in the past 3 months
  • Injection of corticosteroids or anesthesia in the SIJ during the previous 1 month
  • Psychological disorders affecting the subject's ability to follow the instructions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: KC + MWM Group
Group A will receive routine physical therapy along with kinetic control training of multifidus and glutues maximus with mulliogan's mobilization with movement.
Other: Kinetic Control + Mobilization with Movement

Participants will receive baseline therapy consisting of superficial heating therapy followed by structured stretching and strengthening exercises for the sacroiliac joint and lumbar region on mat. Then Mulligan's MWM will be applied to the sacroiliac joint using sustained accessory glides combined with pain-free active movement. This will be followed by kinetic control training targeting the gluteus maximus and multifidus muscles. Gluteus maximus retraining will be performed in supported positions emphasising controlled hip extension with the knee flexed while maintaining lumbo-pelvic neutrality.

Multifidus retraining will target the deep segmental lumbar extensors with contribution from the deep thoracic extensors. Training will begin in crook lying with a pillow or thick folded towel under the sacrum to elevate the pelvis and allow the lumbar spine to relax while thoracic spine remians neutral. Each session lasts 45 minutes. The intervention will be delivered for 8 weeks.
Active Comparator: MWMGroup
Group B will receive routine physical therapy along with Mulligan's mobilization with movement.
Other: Mobilization with Movement
Participants will receive baseline therapy consisting of superficial heating therapy followed by structured stretching and strengthening exercises for the sacroiliac joint and lumbar region on mat. Mulligan's MWM will be applied according to standard Mulligan principles. Participants will be classified as having anterior or posterior ilial rotation based on physical examination findings. For anterior rotation, a sustained posterior glide to the affected ilium with sacral stabilization will be applied during prone press-up. For posterior rotation, an anterolateral glide will be delivered over the posterior superior iliac spine with counter-pressure to the opposite ilium. Mobilization will be performed in non-weight-bearing for 3 sets of 10 repetitions per session, within a pain-free range, over 8 weeks (3 sessions/week).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Numeric Pain Rating Scale (NPRS)
Time Frame: 8 weeks
The intensity of pain was measured by using the NPRS, a scale of 11 points starting from 0 to 10, where 0 represents no pain and 10 represents the worst possible pain. The NPRS has been found to possess good construct validity by showing strong correlation with other pain intensity measurement tools. This scale has also been found to possess consistent reliability (ICC: 0.58 to 0.88), especially in patients experiencing neck pain. The application of this scale has also been found to extend beyond patients experiencing musculoskeletal disorders.
8 weeks
Inclinometer
Time Frame: 8 weeks
ROM was measured by using an inclinometer to measure joint movement quantitatively. Inclinometer has been found to possess superior reliability over a goniometer for measuring ROM. High intrarater reliability values (ICC>0.90) has been observed for inclinometers, indicating excellent consistency of measurement by a tester. High reliability has also been found for medical and digital types of inclinometers (ICC ≈ 0.91-0.95). For measuring ROM two inclinometers were fixed, with one placed over the T12 spinous process and the other over the S1 spinous process. This helped to measure the ROM of lumbar spine, keeping the effects of hip and sacral joints at a minimum. The ROM of lumbar spine was measured by using a dual inclinometer technique, keeping one over the superior aspect of T12 and the other over the inferior aspect of S1. The subjects were asked to perform various types of lumbar spine movements by keeping their knees straight.
8 weeks
Observational Gait Analysis (OGA)
Time Frame: 8 weeks
Gait assessment was carried out by using observational gait analysis (OGA), which is a structured assessment of gait using standardized gait assessment scales. It helps to assess and quantify abnormalities of gait through visual observation. The basic framework of OGA is a 5-point scale, where each gait parameter is scored during the stance and swing phases. The clinician first observes the gait cycle of the patient, focusing on the kinematic gait patterns including pelvic alignment during initial contact of the foot and knee flexion during the mid-swing phase. The OGA form provides a connection between qualitative and quantitative assessment of gait. This heps in the development of a rehabilitation program for each patient.
8 weeks
Modified Oswestry Disability Index (MODI)
Time Frame: 8 weeks

Functional disability was measured using MODI, a self reported questionnaire that was designed to measure disability related to low back and lumbopelvic disorders. MODI follows the same scoring system and disability interpretation criteria as the original ODI. It consists of 10 sections that include pain intensity, personal care (e.g., washing and dressing etc), lifting, walking, sitting, standing, sleeping, social life, travelling and eployment/home making. Each scored from 0 to 5, yielding a maximum total score of 50 points (or 45 points if 1 section is omitted). The final score is calculated by formula:

Patient's total score / total possible score × 100

The percentage score is interpreted as follows:

  • 0-20% : minimal disbability
  • 21-40% : moderate disability
  • 41-60% : severe disability
  • 61-80% : crippling disability where pain impinges on all aspects of patient's life
  • 81-100%: patients are bed bound a minimum change of 10% is necessary to reflect reliable change in disability
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Lahore University of Biological and Applied Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 15, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 7, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 14, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 26, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • UBAS/ERB/FoRS/25/019

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sacroiliac Joint Dysfunction

Clinical Trials on Kinetic Control + Mobilization with Movement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings